Sindy T. Kim

Full Professor(heuristic)

Renal cell carcinoma treatment · Pulmonary and Respiratory Medicine

h-index18

i10-index22

Publications35

Citations14,301

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 13 of 13

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology · 2023-04-05 · 167 citations
Data from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Data from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023-03-31
Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023-03-31
Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31
Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthPreprint
2023-03-31

Open author page on OpenAlex →